Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02463344 · ClinicalTrials.gov registry record
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
A clinical trial of Age-related Macular Degeneration, sponsored by Astellas Institute for Regenerative Medicine.
- Completed
- Registry status
- 11
- Enrollment target
- 4
- Study locations
NCT02463344 is a study of Age-related Macular Degeneration that has completed, run by Astellas Institute for Regenerative Medicine. The registered enrollment target is 11 participants, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02463344, a study of Age-related Macular Degeneration, has completed, sponsored by Astellas Institute for Regenerative Medicine.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of his study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry Age-Related Macular Degeneration (AMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.
Conditions Studied
Interventions
- BIOLOGICAL MA09-hRPE
Study Locations (4)
California
- Jules Stein Eye Institute, UCLA School of Medicine - Los Angeles
Florida
- Bascom Palmer Eye Institute - Miami
Massachusetts
- Mass Eye and Ear - Boston
Pennsylvania
- Wills Eye Institute-Mid Atlantic Retina - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-02-25 |
| Est. Completion | 2019-08-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02463344
The ClinicalTrials.gov registry entry for NCT02463344 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The listed sponsor is Astellas Institute for Regenerative Medicine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which MA09-hRPE is the first listed.
NCT02463344 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02463344 about?
NCT02463344 is a clinical study titled "Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD". The purpose of his study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry Age-Related Macular Degeneration (AMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.
What is the current status of trial NCT02463344?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2013-02-25. Estimated completion is 2019-08-19.
What conditions does trial NCT02463344 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT02463344?
The interventions under investigation include: MA09-hRPE (BIOLOGICAL).
Who is sponsoring clinical trial NCT02463344?
This trial is sponsored by Astellas Institute for Regenerative Medicine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02463344 being conducted?
This trial has 4 study locations across California, Florida, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.